SCHEMBL5115032

SCHEMBL5115032

CN(C)S(=O)(=O)c1ccc(Nc2ncnc3sc(Nc4c(Cl)cccc4Cl)nc23)cc1

nearest known ligand 0.80

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 18/20 0.80
PIP4K2A P48426 1/20 0.53
PIP4K2B P78356 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5103956 0.90 TRPV1 (0.65) TRPV1PIP4K2APIP4K2B
SCHEMBL5105522 0.90 TRPV1 (0.66) TRPV1PIP4K2APIP4K2B
SCHEMBL14289484 0.89 TRPV1 (1.00) TRPV1PIP4K2A
SCHEMBL5115228 0.86 TRPV1 (0.60) TRPV1
SCHEMBL3929033 0.83 TRPV1 (0.61) TRPV1
SCHEMBL14289479 0.82 TRPV1 (1.00) TRPV1PIP4K2A
SCHEMBL14289485 0.82 TRPV1 (0.84) TRPV1PIP4K2A
SCHEMBL3940960 0.81 TRPV1 (1.00) TRPV1
SCHEMBL14289435 0.80 TRPV1 (1.00) TRPV1
SCHEMBL14289505 0.80 TRPV1 (0.84) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US claimed
WO-2008005303-A2 THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-10 WO disclosed
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US disclosed
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US disclosed
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004253-A1 Thiazolopyrimidine modulators of TRPV1 TRPV1, TRPA1, TRPV2 TRPV1 1/4885PIP4K2A 1644/4885PIP4K2B 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.